A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI

Open source

DOI: 10.1158/2767-9764.crc-26-0488
Published: 2026 Sep 1
Container: Cancer research communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-26-0488,
  title = {A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.},
  author = {Choudhury AD and Zhong C and Xie W and Kochupurakkal BS and Wu PI and Riaz IB and Liu R and Yang DD and Folefac E and Lee D and Parikh M and Einstein DJ and Kessler ER and Mayer T and McKay RR and Pace A and Mouw KW and Chen L and Adalsteinsson VA and Van Allen EM and Kunos CA and Gore SD and Das B and D'Andrea A and Taplin ME and Shapiro GI},
  year = {2026},
  journal = {Cancer research communications},
  doi = {10.1158/2767-9764.crc-26-0488},
  url = {https://doi.org/10.1158/2767-9764.crc-26-0488}
}

RIS

TY  - JOUR
TI  - A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.
AU  - Choudhury AD
AU  - Zhong C
AU  - Xie W
AU  - Kochupurakkal BS
AU  - Wu PI
AU  - Riaz IB
AU  - Liu R
AU  - Yang DD
AU  - Folefac E
AU  - Lee D
AU  - Parikh M
AU  - Einstein DJ
AU  - Kessler ER
AU  - Mayer T
AU  - McKay RR
AU  - Pace A
AU  - Mouw KW
AU  - Chen L
AU  - Adalsteinsson VA
AU  - Van Allen EM
AU  - Kunos CA
AU  - Gore SD
AU  - Das B
AU  - D'Andrea A
AU  - Taplin ME
AU  - Shapiro GI
PY  - 2026
JO  - Cancer research communications
DO  - 10.1158/2767-9764.crc-26-0488
UR  - https://doi.org/10.1158/2767-9764.crc-26-0488
ER  -

APA

AD, C., C, Z., W, X., BS, K., PI, W., IB, R., R, L., DD, Y., E, F., D, L., M, P., DJ, E., ER, K., T, M., RR, M., A, P., KW, M., L, C., VA, A., EM, V. A., CA, K., SD, G., B, D., A, D., ME, T., & GI, S. (2026). A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.. Cancer research communications. https://doi.org/10.1158/2767-9764.crc-26-0488

Source records

pubmed · retrieved 2026-09-26T05:29:59.933Z